Typed or printed name

Signature

Brian C. Remy

February 4, 2005

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 09/994,412 **TRANSMITTAL** Filing Date **November 27, 2001 FORM** First Named Inventor Ulrich Certa et al. Art Unit 1635 (to be used for all correspondence after initial filing) **Examiner Name** Karen A. Lacourciere **Attorney Docket Number** 20787 Total Number of Pages in This Submission

Total Nulliber of Pages III This Submission			
ENCLOSURES (Check all that apply)			
	Amendme Af	smittal Form ee Attached ent/Reply fter Final ffidavits/declaration(s) of Time Request Abandonment Request	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer After Allowance communication to Group Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
	Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Remarks Amendment & Response to Notice To Comply with Requirements for Patent Applications Containing Nucleotide Squence Disclosures, Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825 and Diskette
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name Brian C. Remy			
Signature Bryan Dew			
Pate February 4, 200		February 4, 20	10.50
CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Ulrich Certa et al.

Group: 1635

Serial No. 09/994,412, filed November 27, 2001

Examiner: Karen A. Lacourciere

For: INHIBITION OF EXPRESSION OF A TARGET GENE

AMENDMENT & RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE DISCLOSURES

Nutley, New Jersey 07110 February 4, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence Disclosures," mailed January 6, 2005, Applicants submit herewith: (1) a computer readable form (CRF) copy of the sequence listing; (2) a paper copy of the sequence listing; (3) a statement that the content of the paper and computer readable copies are the same and includes no new matter pursuant to 37 C.F.R. 1.821; and (4) instructions amending the specification to include specific SEQ ID NO: identifiers in the specification.

Please amend the above-identified application as follows: